Intuitive Surgical Announces $16.0 Million Fourth Quarter Revenue, Up 50%; Full Year 2001 Revenue $51.7 Million, Up 94%

February 7, 2002 at 4:08 PM EST
MOUNTAIN VIEW, Calif., Feb 7, 2002 (BUSINESS WIRE) -- Intuitive Surgical, Inc. (Nasdaq:ISRG), the leader in operative surgical robotics, today reported sales of $16.0 million in the fourth quarter of 2001, up 50% from $10.7 million in sales reported in the fourth quarter of 2000. The sale of 15 da Vinci(TM) Surgical Systems drove fourth quarter 2001 revenue growth, compared with 11 da Vinci(TM) Surgical Systems in the fourth quarter of 2000. Fourth quarter 2001 sales increased $5.1 million, or 47%, compared to third quarter 2001. Intuitive reported full fiscal year 2001 sales of $51.7 million, up 94% over $26.6 million for fiscal year 2000. The total cumulative placements of da Vinci(TM) Surgical Systems is now 89.

Total fourth quarter 2001 systems sales were $13.7 million, instruments and accessories $1.6 million, and service revenue $0.7 million. The following table compares fourth quarter and fiscal year 2001 revenue to the prior year.

                         Q401    Q400   Incr.    FY01     FY00   Incr.
                         ----    ----   -----    ----     ----   -----
Revenue ($ Millions)
Systems                 $13.7  $ 9.8   $ 3.9    $44.7   $23.5   $21.2
Instruments/Accys       $ 1.6  $ 0.7   $ 0.9    $ 5.0   $ 2.5   $ 2.5
Service                 $ 0.7  $ 0.2   $ 0.5    $ 2.0   $ 0.6   $ 1.4
                        -----  -----   -----    -----   -----   -----
                        $16.0  $10.7   $ 5.3    $51.7   $26.6   $25.1
System Population
Placements                 15     11       4       49      28      21
Cumulative Placements      89     40      49       89      40      49
Gross margin for the fourth quarter of 2001 was 49%, compared with 41% for the fourth quarter of 2000, excluding non-routine royalty charges in both quarters, and 47% in the third quarter of 2001. Gross margin improvement was due primarily to higher sales and manufacturing overhead cost efficiency. Fourth quarter 2001 and fourth quarter 2000 margin were both negatively impacted by $1 million due to non-routine royalty charges taken to cost of sales. Including the impact of non-routine royalty expenses, fourth quarter margins were 42% in 2001 and 32% in 2000. No future royalty charges are called for under existing agreements.

Excluding the impact of the non-routine royalty charges, net loss for the fourth quarter of 2001 was $3.3 million, compared to a net loss of $4.0 million for the fourth quarter of 2000 and $4.8 million for the third quarter of 2001. Including the impact of the non-routine royalty charges, fourth quarter 2001 net loss was $4.3 million and fourth quarter 2000 was $5.0 million. Fourth quarter 2001 basic and diluted net loss per share was $0.09, or $0.12 including non-routine royalty, compared to a net loss per share of $0.11, or $0.14, including non-routine royalty for the fourth quarter of 2000 and $0.13 for the third quarter of 2001.

Net Loss for the fiscal year ending December 31, 2001 was $16.7 million compared to a net loss of $18.5 million for fiscal year 2000.

Commenting on the announcement, Lonnie Smith, President and CEO of Intuitive Surgical said: "We are very pleased with our record fourth quarter revenue and the continued growth of our business. We see system usage continuing to increase as the da Vinci(TM) Surgical System demonstrates its value in the modern operating room."

The company will also discuss these results at a conference call today at 1:30 PM PT. The dial-in numbers for this call are 888-809-8965 for U.S. calls and 212-287-1616 for international calls. The passcode is ISRG and the meeting leader is Mr. Lonnie Smith.

    About the da Vinci(TM) Surgical System:
The da Vinci(TM) Surgical System consists of a surgeon's viewing and control console having an integrated, high-performance InSite(TM) 3-D vision system, a patient-side cart consisting of three robotic arms that position and precisely maneuver endoscopic instruments and an endoscope, and a variety of articulating EndoWrist(TM) Instruments. By integrating computer-enhanced technology with surgeons' technical skills, Intuitive believes that its System enables surgeons to perform better surgery in a manner never before experienced. The da Vinci(TM) Surgical System seamlessly and directly translates the surgeon's natural hand, wrist and finger movements on instrument controls at the surgeon's console outside the patient's body into corresponding micro-movements of the instrument tips positioned inside the patient through small puncture incisions, or ports.

The statements contained in this release may be deemed to contain "forward-looking statements." Such statements are indicated by words or phrases such as "anticipate," "estimate," "projects," "believes," "intends," "expects" and similar words and phrases. Actual results may differ materially from those expressed or implied in any forward-looking statement as a result of certain risks and uncertainties, including, without limitation, competition and market acceptance of the Company's products, ability to obtain regulatory approvals and third-party reimbursement, ability to raise additional capital and other risks and uncertainties detailed in the Company's Securities and Exchange Commission filings. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.

Note to Editors: Intuitive(R), da Vinci(TM), InSite(TM), and EndoWrist(TM) are trademarks of Intuitive Surgical, Inc.

                   INTUITIVE SURGICAL, INCORPORATED
           CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
                 (IN THOUSANDS, EXCEPT PER SHARE DATA)
                                               Three months ended
                                           December 31,   December 31,
                                              2001           2000
                                              ----           ----
Sales                                      $ 16,013        $ 10,706
Cost of sales                                 9,246           7,289
                                           --------        ---------
  Gross profit                                6,767           3,417
Operating costs and expenses:
  Research and development                    3,791           3,110
  Selling, general and administrative         8,034           6,626
                                           ---------       ---------
    Total operating costs and expenses       11,825           9,736
Loss from operations                         (5,058)         (6,319)
Interest income/(expense)                       806           1,337
                                           ---------       ---------
Net loss                                   $ (4,252)       $ (4,982)
                                           =========       =========
Weighted average shares outstanding
 used to compute net loss per share          36,147          35,139
                                           ---------       ---------
Loss per share - basic and diluted         $  (0.12)       $  (0.14)
                                           =========       =========
                   INTUITIVE SURGICAL, INCORPORATED
           CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
                 (IN THOUSANDS, EXCEPT PER SHARE DATA)
                                                Fiscal year ended
                                            December 31,  December 31,
                                               2001          2000
                                               ----          ----
Sales                                       $  51,673      $ 26,624
Cost of sales                                  28,218        18,031
                                             --------      --------
  Gross profit                                 23,455         8,593
Operating costs and expenses:
  Research and development                     13,851        11,734
  Selling, general and administrative          29,987        19,136
                                             --------     ---------
     Total operating costs and expenses        43,838        30,870
Loss from operations                          (20,383)      (22,277)
Interest income/(expense)                       3,683         3,754
                                             ---------    ---------
Net loss                                    $ (16,700)    $ (18,523)
                                             =========    =========
Weighted average shares outstanding
 used to compute net loss per share            35,815        23,796
                                             ---------     ---------
Loss per share - basic and diluted          $   (0.47)    $   (0.78)
                                            ==========    ==========
                   INTUITIVE SURGICAL, INCORPORATED
                CONSOLIDATED BALANCE SHEETS (UNAUDITED)
                            (IN THOUSANDS)
                                             December 31,  December 31,
                                                 2001          2000
                                                 ----          ----
Assets
Current assets:
  Cash, cash equivalents and
   short-term investments                     $   66,661   $   89,441
  Accounts receivable, net                        13,248        6,444
  Inventories, net                                 6,182        6,076
  Prepaid expenses                                 3,128        1,705
                                              -----------  ----------
      Total current assets                        89,219      103,666
Property and equipment, net                        7,834        4,669
Other assets                                       3,308        4,086
                                              -----------  ----------
      Total assets                            $  100,361   $  112,421
                                              ===========  ==========
Liabilities and stockholders' equity
Current Liabilities:
  Accounts payable                            $    8,300   $    7,128
  Accrued compensation and employee benefits       2,537        2,609
  Warranty provision                               1,831        1,494
  Accrued Royalty                                  1,000        1,000
  Accrued liabilities                              2,128        2,028
  Deferred revenue                                 3,870        3,552
  Current portion of notes payable                 1,631        2,019
                                              -----------   ---------
    Total current liabilities                     21,297       19,830
Notes payable                                        771        1,861
Stockholders' equity
Common stock                                          36           36
  Additional paid-in capital                     188,962      186,713
  Deferred compensation                             (886)      (2,483)
  Accumulated deficit                           (110,370)     (93,670)
  Accumulated other comprehensive income             551          134
                                              -----------   ----------
    Total stockholders' equity                    78,293       90,730
Total liabilities and stockholders' equity    $  100,361    $ 112,421
                                              ==========    =========
CONTACT: Intuitive Surgical, Inc. Ben Gong, 650/237-7075 Sarah Norton, 650/237-7191